Tags

Type your tag names separated by a space and hit enter

Mammographic changes during postmenopausal hormonal replacement therapy with tibolone.
Eur J Gynaecol Oncol. 2004; 25(4):493-4.EJ

Abstract

PURPOSE OF INVESTIGATION

To evaluate mammographic changes in postmenopausal women receiving hormonal replacement therapy (HRT) with tibolone.

METHODS

83 postmenopausal women aged 45-62 received the same dose of tibolone for a period of six months to five years without interruption. The women were examined mammographically every six to 12 months during the observation period.

RESULTS

There was a low incidence of breast tenderness. Also, we did not observe any significantly increased mammographic density or neoplasmatic disease of the breast. As far as dysplastic changes are concerned, no remarkable aggravation in the mammographic picture was noted.

CONCLUSION

The new synthetic steroid tibolone, in contrast to conventional HRT, rarely causes breast pain. At least short-period tibolone therapy (less than 5 years) has good effects on climacteric disorders and does not cause breast changes (dysplasia or cancer). Our study is on-going.

Authors+Show Affiliations

Department of Cytopathology, Theagenio Anticancer Hospital of Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15285312

Citation

Pantidou, A, et al. "Mammographic Changes During Postmenopausal Hormonal Replacement Therapy With Tibolone." European Journal of Gynaecological Oncology, vol. 25, no. 4, 2004, pp. 493-4.
Pantidou A, Kaplanis K, Chrissogonidis I, et al. Mammographic changes during postmenopausal hormonal replacement therapy with tibolone. Eur J Gynaecol Oncol. 2004;25(4):493-4.
Pantidou, A., Kaplanis, K., Chrissogonidis, I., & Destouni, C. (2004). Mammographic changes during postmenopausal hormonal replacement therapy with tibolone. European Journal of Gynaecological Oncology, 25(4), 493-4.
Pantidou A, et al. Mammographic Changes During Postmenopausal Hormonal Replacement Therapy With Tibolone. Eur J Gynaecol Oncol. 2004;25(4):493-4. PubMed PMID: 15285312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mammographic changes during postmenopausal hormonal replacement therapy with tibolone. AU - Pantidou,A, AU - Kaplanis,K, AU - Chrissogonidis,I, AU - Destouni,C, PY - 2004/8/3/pubmed PY - 2004/8/26/medline PY - 2004/8/3/entrez SP - 493 EP - 4 JF - European journal of gynaecological oncology JO - Eur. J. Gynaecol. Oncol. VL - 25 IS - 4 N2 - PURPOSE OF INVESTIGATION: To evaluate mammographic changes in postmenopausal women receiving hormonal replacement therapy (HRT) with tibolone. METHODS: 83 postmenopausal women aged 45-62 received the same dose of tibolone for a period of six months to five years without interruption. The women were examined mammographically every six to 12 months during the observation period. RESULTS: There was a low incidence of breast tenderness. Also, we did not observe any significantly increased mammographic density or neoplasmatic disease of the breast. As far as dysplastic changes are concerned, no remarkable aggravation in the mammographic picture was noted. CONCLUSION: The new synthetic steroid tibolone, in contrast to conventional HRT, rarely causes breast pain. At least short-period tibolone therapy (less than 5 years) has good effects on climacteric disorders and does not cause breast changes (dysplasia or cancer). Our study is on-going. SN - 0392-2936 UR - https://www.unboundmedicine.com/medline/citation/15285312/Mammographic_changes_during_postmenopausal_hormonal_replacement_therapy_with_tibolone_ L2 - https://medlineplus.gov/mammography.html DB - PRIME DP - Unbound Medicine ER -